Amarin Plans to Increase VASCEPA® (icosapent ethyl) Promotion and Education

NEXT STORY
Mayo Clinic joins Biomerica’s InFoods® Irritable Bowel Syndrome (“IBS”) Diagnostic-Guided Therapy clinical trial
PREV STORY
Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Adaptimmune Reports First Quarter 2018 Financial Results and Business Update

- Dosing patients in MAGE-A10 lung cancer study at one billion target cell dose ...

author_avatar
NASDAQ Market News

Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML

author_avatar
NASDAQ Market News

BeyondSpring Summarizes Key Messages from KOL Call regarding Lead Asset Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia

NEW YORK , Feb. 05, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global ...

author_avatar
NASDAQ Market News